NASDAQ$MGTX
MeiraGTx Holdings plc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
MeiraGTx reported Q1 2026 total revenue of $293K and a net loss of $46.3M.
For the three months ended March 31, 2026, MeiraGTx reported total revenue of $0.3 million versus $1.9 million in Q1 2025 and a net loss of $46.3 million. R&D expense was $32.0 million and G&A $8.9 million. The gene therapy company continues pivotal programs with limited collaboration revenue in the quarter.
- Total revenue $0.3M; almost entirely collaboration/service related.
- Net loss $46.3M vs $40.0M prior-year quarter.
- R&D $32.0M remains the dominant spend category.
- Foreign currency loss $(2.8)M in other expense.
- Cash runway and partnership funding discussed in liquidity section.
Headline financials
Revenue & EPS history
MeiraGTx · Revenue · Quarterly
$293K
Forward guidance
Gene therapy developer without product revenue guidance; milestones tied to clinical readouts and partnered program funding.
Tailwinds
- Disciplined G&A relative to R&D scale.
- Pipeline optionality in ophthalmology and neurodegenerative programs.
Headwinds
- Minimal quarterly revenue increases net loss funding needs.
- FX headwinds on non-US operations.
- Clinical and regulatory risks for AAV programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2026
+0.1%
Avg return
Earnings day
-0.3%
Avg return
5 days after
-0.0%
Avg return
30 days after
31%
10 / 32 earnings
Positive
+25.0%
Q1 2019
Best reaction
-20.4%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.0% | -6.1% | — | |
| Q1 2026 | -0.2% | -8.4% | -3.7% | |
| Q3 2025 | -4.5% | -10.5% | +3.0% | |
| Q2 2025 | -0.1% | -9.1% | -8.8% | |
| Q1 2025 | -0.4% | +5.2% | +31.5% | |
| Q4 2024 | +1.3% | +17.0% | -18.9% | |
| Q3 2024 | -0.3% | -8.6% | -8.1% | |
| Q2 2024 | -3.4% | -3.2% | -4.8% | |
| Q1 2024 | -1.4% | +1.8% | -7.2% | |
| Q4 2023 | +0.0% | -1.1% | -12.4% | |
| Q3 2023 | +4.7% | +19.2% | -1.3% | |
| Q2 2023 | +5.6% | +1.6% | -3.8% | |
| Q1 2023 | -6.9% | +12.9% | +30.2% | |
| Q4 2022 | -3.4% | -11.9% | -8.3% | |
| Q3 2022 | -7.3% | -6.3% | -13.2% | |
| Q2 2022 | +14.4% | +7.0% | -5.9% | |
| Q1 2022 | -3.1% | -5.9% | -15.0% | |
| Q4 2021 | -2.4% | -5.0% | -7.1% | |
| Q3 2021 | -1.7% | -1.7% | +1.8% | |
| Q2 2021 | -0.9% | -8.3% | -16.2% | |
| Q1 2021 | -2.4% | -3.7% | +10.2% | |
| Q4 2020 | +8.0% | +9.1% | -17.3% | |
| Q3 2020 | -1.7% | +4.1% | -6.9% | |
| Q2 2020 | +5.1% | +5.6% | -3.7% | |
| Q1 2020 | +7.8% | +16.1% | +8.0% | |
| Q4 2019 | -20.4% | -38.8% | -11.1% | |
| Q3 2019 | +1.7% | +6.7% | +49.4% | |
| Q2 2019 | -10.6% | -15.2% | -22.9% | |
| Q1 2019 | +25.0% | +32.1% | +23.5% | |
| Q4 2018 | -3.0% | -3.7% | +3.4% | |
| Q3 2018 | -2.6% | -5.3% | -5.5% | |
| Q2 2018 | +7.9% | +6.2% | +40.7% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro